IDH2 and glioblastoma: WHO grade IV diffuse glioma have traditionally been referred to as GBM, yet they are comprised of two molecularly and clinically distinct diseases-based presence or absence of mutations in isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2).